13.2 Bioethics, Informed Consent & Quality Improvement in Oncology

9.2 Bioethics, Informed Consent & Quality Improvement in Oncology

Advanced Practice Registered Nurses (APRNs) in oncology routinely navigate challenging bioethical dilemmas, clinical trial protocols, and quality improvement initiatives. Ensuring patient self-determination, ethical research conduct, and robust quality measures is essential for delivery of safe, equitable cancer care.

---

The Four Core Principles of Biomedical Ethics

Oncology practice involves high-stakes decision-making regarding aggressive antineoplastic therapy, phase I clinical trial participation, and end-of-life care. The classic Beauchamp and Childress bioethical framework outlines four primary principles:

1. Autonomy

Autonomy recognizes the moral right of competent individuals to make self-determining healthcare decisions. In oncology, this principle underlies informed consent, the right to refuse chemotherapy or radiation, advance directive execution, and appointment of a surrogate decision-maker (Durable Power of Attorney for Healthcare). APRNs must ensure patients receive unbiased, comprehensive disclosures regarding disease prognosis, treatment goals, and risk profiles free from coercion.

2. Beneficence

Beneficence imposes an affirmative duty on healthcare providers to act in the best interest of the patient. In oncology, beneficence involves recommending evidence-based antineoplastic treatments to achieve disease remission, palliate debilitating cancer symptoms, and optimize quality of life.

3. Non-Maleficence

Non-maleficence dictates "first, do no harm" (primum non nocere). Because virtually all antineoplastic agents carry significant toxicity (e.g., myelosuppression, cardiotoxicity, neurotoxicity), APRNs must carefully weigh potential therapeutic gains against treatment burdens. Withdrawing futile, toxic chemotherapy when risks far outweigh clinical benefit aligns directly with non-maleficence.

4. Justice

Justice demands fair, equitable distribution of healthcare resources and equal access to clinical trials, cancer screening, and novel targeted therapies regardless of socioeconomic status, race, or geographic location.

---

Clinical Research Ethics & The Belmont Report

All human subjects research in oncology must comply with federal regulations (Common Rule / 45 CFR 46) rooted in The Belmont Report (1979). The report establishes three overarching ethical principles for human research:

• Respect for Persons: Asserts that individuals are autonomous agents and requires special protection for vulnerable populations (e.g., pediatric patients, cognitively impaired individuals, prisoners, economically disadvantaged persons). It forms the foundation for voluntary informed consent.
• Beneficence: Mandates maximizing potential benefits while minimizing potential risks to research participants.
• Justice: Requires equitable selection of research subjects so that no single demographic group bears unfair research burdens or is denied potential trial benefits.

Institutional Review Board (IRB) Oversight & Review Levels

Every clinical research protocol must receive approval from an Institutional Review Board (IRB) prior to study activation. IRBs categorize protocol reviews into three distinct risk tiers:

Clinical Trial Phases in Oncology

• Phase I: Evaluates safety, pharmacokinetics, Maximum Tolerated Dose (MTD), and Dose-Limiting Toxicities (DLTs) in small patient cohorts.
• Phase II: Evaluates therapeutic efficacy and safety for specific tumor types.
• Phase III: Compares the investigational agent against standard-of-care therapy in large randomized controlled trials.
• Phase IV: Post-marketing surveillance to monitor long-term safety and rare adverse events.

---

Standards of Informed Consent in Oncology

Informed consent is an ongoing communication process, not merely a signed document. Key elements of valid informed consent include:

• Full disclosure of diagnosis, disease stage, and natural disease progression without treatment
• Explanation of proposed treatment mechanisms, administration schedule, and expected benefits
• Comprehensive review of potential toxicities, short-term and long-term risks, and mortality risks
• Discussion of reasonable alternative therapies (including standard-of-care, alternative trials, or palliative/hospice care)
• Explicit affirmation of voluntary participation and the patient's right to withdraw consent at any time without compromising ongoing standard clinical care
• Provision of consent documents written in clear, plain language (target 6th to 8th-grade reading level)

---

Quality Improvement (QI) & Patient Safety Methodologies

Quality improvement in oncology strives to enhance clinical outcomes, eliminate care delivery errors, and maintain alignment with national benchmarks.

ASCO Quality Oncology Practice Initiative (QOPI®)

The American Society of Clinical Oncology (ASCO) QOPI® program provides oncology practices with evidence-based performance measures. Key QOPI core quality metrics include:

• Documentation of clinical staging prior to initiating antineoplastic therapy
• Molecular biomarker testing prior to targeted therapy administration (e.g., HER2 in breast cancer, EGFR/ALK/ROS1 in NSCLC, BRAF in melanoma)
• Standardized assessment of pain and emesis at every clinical encounter
• Formal documentation of chemotherapy consent prior to cycle 1
• Timely referral and involvement of palliative care services
• Adherence to evidence-based antiemetic guidelines for high/moderate emetogenic chemotherapy

Plan-Do-Study-Act (PDSA) Cycles

The PDSA cycle is an iterative four-stage model for continuous quality improvement:

1. Plan: Identify a clinical process flaw, formulate an objective, and plan an intervention.
2. Do: Implement the test intervention on a small pilot scale.
3. Study: Collect data, analyze results, and compare outcomes against pre-intervention baseline metrics.
4. Act: Adopt, adapt, or abandon the intervention based on data findings, then prepare for broader implementation.

Root Cause Analysis (RCA) vs. FMEA

When a sentinel event or near-miss medication error occurs (e.g., wrong-dose vincristine administration or intrathecal medication error), APRNs participate in structured safety analyses:

• Root Cause Analysis (RCA): A retrospective safety investigation designed to identify underlying latent systemic vulnerabilities (e.g., ambiguous EHR order entry screens, inadequate double-check workflows, staffing fatigue) rather than placing individual blame on clinicians. Common RCA tools include the 5 Whys technique and the Fishbone (Ishikawa) cause-and-effect diagram.
• Failure Mode and Effects Analysis (FMEA): A prospective risk management assessment conducted before implementing a new process to identify potential failure points and prevent harm.